Raymond James analyst Ryan Deschner downgraded Apellis (APLS) to Market Perform from Outperform without a price target after the company entered into an agreement to be acquired by Biogen (BIIB) for $41.00 per share in cash at closing, or $5.6B. Apellis stockholders will also receive a contingent value right for each Apellis share held, entitling the holder to receive two payments of $2 per share each, contingent on certain annual global net sales thresholds being met for Syfovre. The firm does not expect regulatory issues to impede the deal closing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Hold Rating on Apellis Reflects Biogen Takeover Cap on Upside and Limited Near-Term Catalysts
- Apellis Pharmaceuticals to be Acquired by Biogen in Merger
- Apellis downgraded to Neutral from Overweight at Cantor Fitzgerald
- Apellis downgraded to Hold from Buy at Stifel
- Apellis downgraded to Neutral from Buy at Citi